Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 5/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PDXK | O00764 | 1/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23270227 | 0.80 | DHFR (0.34) | — | |
| SCHEMBL14320248 | 0.78 | RXFP1 (0.39) | RXFP1NUDT1GRM4KDM4EALDH1A1 | |
| SCHEMBL21757338 | 0.78 | GRM4 (0.36) | NUDT1GRM4ALDH1A1 | |
| SCHEMBL16462868 | 0.78 | BCL6 (0.37) | RXFP1GRM4ALDH1A1PIK3CA | |
| SCHEMBL6369153 | 0.77 | PDE10A (0.38) | LMNAPDXK | |
| Benzene SCHEMBL28603598 | 0.77 | DHFR (0.38) | — | |
| SCHEMBL15429615 | 0.76 | NUDT1 (0.37) | NUDT1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28467294 | 0.76 | PDE10A (0.38) | PDXK | |
| SCHEMBL22074101 | 0.74 | PDXK (0.31) | PDXK | |
| SCHEMBL28988161 | 0.74 | ALDH1A1 (0.40) | KDM4EALDH1A1PDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | RICE KENNETH D (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2012074869-A1 | BENZOXAZEPINES AS INHIBITORS OF PI3K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-06-07 | — | — | WO | disclosed |
| WO-2012071511-A1 | BENZOXAZEPINES AS INHIBITORS OF MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012071519-A1 | BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE | EXELIXIS, INC. (US) | 2012-05-31 | — | — | WO | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | TARGEGEN, INC. (US) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018347-A1 | BENZOXAZEPINES AS INHIBITORS OF mTOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RICTOR, RPTOR | RXFP1 3802/4885NUDT1 3866/4885GRM4 838/4885 |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | RXFP1 3494/4885NUDT1 3773/4885GRM4 1053/4885 |
| US-20140073628-A1 | BENZOXAZEPINES ASN INHIBITORS OF P13K/M TOR AND METHODS OF THEIR USE AND MANUFACTURE | MTOR, RPTOR, RICTOR | RXFP1 3988/4885NUDT1 4350/4885GRM4 1437/4885 |
| US-20070149508-A1 | Six membered heteroaromatic inhibitors targeting resistant kinase mutations | ABL1, KDR, BCR | RXFP1 4473/4885NUDT1 2963/4885GRM4 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.